ALSO NOTED: New label for Iressa; Canada rejects Vantas; RegeneRx to raise $60M; and much more...

> AstraZeneca has changed the label on Iressa, restricting its use to patients who have already benefited from the drug or for patients in a clinical trial. A pivotal trial of Iressa had failed to confirm a significant survival benefit from the drug. Release

> Health Canada has requested more information before it can approve Paladin Labs' Vantas. Vantas was developed by Valera and Paladin licensed it for the Canadian market. Article

> RegeneRx of Bethesda, Maryland, has filed a $60 million shelf registration. Release

> Regulators have concluded that four of Columbia University Medical Center's drug trials in the 1990s violated federal rules. Story

> Bayer HealthCare, Diagnostics Division, has granted a license to American Diagnostica to certain cancer marker assays. Release

> Vertex and Merck have launched a Phase I trial with VX-680, a small molecule inhibitor of Aurora kinases. Release

> South San Francisco-based Tercica and Genentech have filed to withdraw a motion for a preliminary injunction against Insmed and Celtrix Pharmaceuticals over the growth hormone SomatoKine. Article

And Finally... Some 18,000 scientists and business leaders are headed to Philadelphia for this year's BIO, and city leaders are clearly hoping for a boost to their biotech sector. Editorial

Suggested Articles

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.